GlassScriptPhysician profile
Barry F Zeffren
NPI 1205908639
$17,768.71
in general payments reported to CMS, 2019-2025
20 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $3,729 · 2021: $4,827 · 2022: $1,986 · 2023: $5,874 · 2024: $611 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,200 · Food and Beverage: $1,627 · Education: $15.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,200.00 |
| Food and Beverage | $1,626.75 |
| Education | $15.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15,027.89 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,207.65 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $356.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $163.74 | 2020-2025 | |
| Alk-Abello, INC | $155.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.86 | 2022-2025 | Eohilia, Cuvitru |
| Grifols USA, LLC | $111.39 | 2021-2023 | Xembify |
| Optinose US, INC. | $107.18 | 2021-2024 | |
| Genentech USA, INC. | $91.62 | 2021-2024 | Xolair |
| Kaleo, INC. | $84.79 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $67.81 | 2021-2023 | Dupixent |
| Pfizer INC. | $58.95 | 2021-2025 | |
| Csl Behring | $48.18 | 2022-2025 | Andembry |
| Biocryst US Sales Co., LLC | $45.75 | 2023-2024 | Orladeyo, Orladeyo |
| Pharming Healthcare, INC. | $31.94 | 2024 | Ruconest |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $28.46 | 2023 | Ryaltris |
| Octapharma USA, INC. | $18.67 | 2022 | |
| Amgen INC. | $17.21 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $15.33 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $14.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Zeffren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.